Status:
TERMINATED
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
Lead Sponsor:
Almirall, S.A.
Conditions:
Plaque Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the psoriasis disease control over time in participants who had received Tildrakizumab for at least the last 5 years and have discontinued it and to describe b...
Eligibility Criteria
Inclusion
- Participants provide signed written informed consent prior to perform any study-related activity
- Participants has completed the long-term extension of the reSURFACE 2 study
Exclusion
- Participants unable to comply with the requirements of the study
- Participants who in the opinion of the investigator should not participate in the study
Key Trial Info
Start Date :
January 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 31 2020
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT04339595
Start Date
January 29 2020
End Date
July 31 2020
Last Update
December 8 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 0003
Lodz, Poland
2
Site 0001
Wroclaw, Poland
3
Site 0002
Wroclaw, Poland